REGN Regeneron Pharmaceuticals margins

Relative Growth: Rel. Growth: 66

Relative Strength: Rel. Strength: 63

Relative Valuation: Rel. Valuation: 49

Relative Profitability: Rel. Profitability: 81

Gross margin

84.9%

Operating margin

24.7%

EBITDA margin

37%

Net margin

27.9%

Currently, Regeneron Pharmaceuticals has a gross margin of 84.9%, an operating margin of 24.7%, an EBITDA margin of 37%, and a net margin of 27.9%. Each available margin declined from the same period last year. Net margin recorded the strongest contraction, decreasing by 3.5 percentage points.

REGN margin history

Gross, operating, EBITDA and net margin trends

Regeneron Pharmaceuticals's margins averaged 85.68% gross, 27.27% operating, 38.09% EBITDA, and 30.95% net over the last 3 years. At present, all four current margins are below their three-year averages.

REGN margin expansion

Year-over-year margin changes in percentage points

All available margins contracted year over year, led by net margin with a decline of 3.5 percentage points.

Gross margin expansion

-0.7pp

Operating margin expansion

-2.3pp

EBITDA margin expansion

-1.1pp

Net margin expansion

-3.5pp

REGN Gross margin

Regeneron Pharmaceuticals's gross margin averaged 85.68% over the last 3 years. At present, the current gross margin for Regeneron Pharmaceuticals is 84.9%, 0.8 percentage points below its three-year average. Over the last 3 years, Regeneron Pharmaceuticals's gross margin peaked at 86.3% in Mar 2024 and reached a low of 84.5% in Mar 2026.

REGN Operating margin

Regeneron Pharmaceuticals's operating margin averaged 27.27% over the last 3 years. Compared with its three-year average, Regeneron Pharmaceuticals's current operating margin is 24.7% and is 2.6 percentage points below its three-year average. Over the last 3 years, Regeneron Pharmaceuticals's operating margin peaked at 30.9% in Dec 2023 and reached a low of 24.3% in Mar 2026.

REGN EBITDA margin

Regeneron Pharmaceuticals recorded an average EBITDA margin of 38.09% across the last 3 years. Regeneron Pharmaceuticals currently reports an EBITDA margin of 37%, 1.1 percentage points below its three-year average. Over the last 3 years, Regeneron Pharmaceuticals's EBITDA margin peaked at 40.6% in Dec 2025 and reached a low of 34.7% in Mar 2024.

REGN Net margin

Across the last 3 years, Regeneron Pharmaceuticals's net margin averaged 30.95%. The current net margin stands at 27.9%, 3.1 percentage points below its three-year average. Net margin was highest at 33.6% in Sep 2024 and lowest at 27.9% in Jun 2026.

REGN margin group comparison

Margins compared with peer-group, industry and sector averages

With a gross margin of 84.9%, REGN is above the Healthcare sector and its peers average but below the industry average. Compared to its Healthcare sector average of 68.4%, Regeneron Pharmaceuticals's gross margin is 24% higher.

REGN margin peer comparison

Compare margins with selected peers

Frequently asked questions

What is Regeneron Pharmaceuticals's gross margin?

For the period ending Jun 30, 2026, REGN recorded a gross margin of 84.9%.

What is Regeneron Pharmaceuticals's operating margin?

As of Jun 30, 2026, REGN has an operating margin of 24.7%.

What is Regeneron Pharmaceuticals's EBITDA margin?

As of Jun 30, 2026, REGN has an EBITDA margin of 37%.

What is Regeneron Pharmaceuticals's net margin?

As of Jun 30, 2026, REGN has a net margin of 27.9%.

What are the average margins of REGN?

Regeneron Pharmaceuticals's gross, operating, EBITDA, and net margins averaged 85.7% gross, 27.3% operating, 38.1% EBITDA, and 31.0% net over the last 3 years.

What are the highest historical margins of REGN?

In the last 5 years, the highest margins reported by REGN were 87.2% gross in Dec 2022, 55.7% operating in Dec 2021, 60.2% EBITDA in Dec 2021, and 50.2% net in Dec 2021.

What are the lowest historical margins of REGN?

Over the last 5 years, Regeneron Pharmaceuticals's lowest margins were 84.5% gross in Mar 2026, 24.3% operating in Mar 2026, 34.7% EBITDA in Mar 2024, and 27.9% net in Jun 2026.